Apertura Gene Therapy at ESGCT 2026

Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website

Apertura Gene Therapy brings 2 presentations to ESGCT 2026 in Hamburg. Its work centres on an AAV capsid that binds the transferrin receptor to reach the brain after intravenous dosing. It covers a development framework for neurological and neurometabolic disorders and a simplified material transfer route for academic groups to test the capsid.

OrganizationESGCT 2026 Attendance
Apertura Gene Therapy
New York, New York
aperturagtx.com
Biotech
Engineers AAV capsids, including the TfR1-targeting CapX, to deliver gene therapies to the brain after intravenous dosing.
Poster
Wed Oct 28
1:30pm–3:30pm
Establishing a gene therapy development framework for TfR1 CapX, an AAV platform for neurological and neurometabolic disorders
AAVs / non integrative vectors
Poster
Wed Oct 28
1:30pm–3:30pm
Open Aperture: An express MTA framework enabling academic evaluation of an hTfR1-targeting AAV capsid for systemic CNS delivery
AAVs / non integrative vectors

Explore the full ESGCT 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Hamburg. Leave your work email and we’ll be in touch.

Privacy

Download the full ESGCT 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Apertura Gene Therapy

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction